Determinants of the receipt of the 9-valent human papillomavirus vaccine in the first year after introduction in North Carolina. Issue 10 (28th February 2018)
- Record Type:
- Journal Article
- Title:
- Determinants of the receipt of the 9-valent human papillomavirus vaccine in the first year after introduction in North Carolina. Issue 10 (28th February 2018)
- Main Title:
- Determinants of the receipt of the 9-valent human papillomavirus vaccine in the first year after introduction in North Carolina
- Authors:
- Trogdon, Justin G.
Shafer, Paul
Lindsay, Brianna
Coyne-Beasley, Tamera - Abstract:
- Highlights: We described the transition from bi- and quadrivalent HPV vaccines to 9vHPV. The transition from other HPV vaccines to 9vHPV was relatively quick. There were disparities in the diffusion of 9vHPV across North Carolina. Abstract: Objectives: The objective of this study was to describe the transition from bi- and quadrivalent HPV vaccines to 9vHPV in aggregate and identify determinants of the receipt of 9vHPV among youth following the introduction of 9vHPV in North Carolina. Methods: The study used a retrospective cohort design with data from the North Carolina Immunization Registry (NCIR). Our sample included all doses of HPV vaccine administered between July 2015 and October 2016 to age-eligible youth (ages 9–17). We used a logistic regression model to associate individual child-level and ZIP Code Tabulation Area (ZCTA)-level characteristics with an indicator variable for receiving 9vHPV (vs. other HPV vaccines). Results: Youth receiving the HPV vaccine were more likely to receive 9vHPV if they lived in a ZCTA with a larger age-eligible (i.e., 9–17) population, a health professional shortage area, or a higher number of annual outpatient visits per capita. They were less likely to receive 9vHPV if they were older, received a publicly-funded dose, or lived in a ZCTA with a higher percentage of the population with less than a high-school education or a higher number of religious organizations. Conclusions: While the transition from other HPV vaccines to 9vHPV wasHighlights: We described the transition from bi- and quadrivalent HPV vaccines to 9vHPV. The transition from other HPV vaccines to 9vHPV was relatively quick. There were disparities in the diffusion of 9vHPV across North Carolina. Abstract: Objectives: The objective of this study was to describe the transition from bi- and quadrivalent HPV vaccines to 9vHPV in aggregate and identify determinants of the receipt of 9vHPV among youth following the introduction of 9vHPV in North Carolina. Methods: The study used a retrospective cohort design with data from the North Carolina Immunization Registry (NCIR). Our sample included all doses of HPV vaccine administered between July 2015 and October 2016 to age-eligible youth (ages 9–17). We used a logistic regression model to associate individual child-level and ZIP Code Tabulation Area (ZCTA)-level characteristics with an indicator variable for receiving 9vHPV (vs. other HPV vaccines). Results: Youth receiving the HPV vaccine were more likely to receive 9vHPV if they lived in a ZCTA with a larger age-eligible (i.e., 9–17) population, a health professional shortage area, or a higher number of annual outpatient visits per capita. They were less likely to receive 9vHPV if they were older, received a publicly-funded dose, or lived in a ZCTA with a higher percentage of the population with less than a high-school education or a higher number of religious organizations. Conclusions: While the transition from other HPV vaccines to 9vHPV was relatively quick, there were disparities in the diffusion of 9vHPV across North Carolina. … (more)
- Is Part Of:
- Vaccine. Volume 36:Issue 10(2018)
- Journal:
- Vaccine
- Issue:
- Volume 36:Issue 10(2018)
- Issue Display:
- Volume 36, Issue 10 (2018)
- Year:
- 2018
- Volume:
- 36
- Issue:
- 10
- Issue Sort Value:
- 2018-0036-0010-0000
- Page Start:
- 1310
- Page End:
- 1315
- Publication Date:
- 2018-02-28
- Subjects:
- Human papillomavirus -- Vaccination
Vaccines -- Periodicals
615.372 - Journal URLs:
- http://www.sciencedirect.com/science/journal/0264410X ↗
http://www.clinicalkey.com/dura/browse/journalIssue/0264410X ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0264410X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.vaccine.2018.01.014 ↗
- Languages:
- English
- ISSNs:
- 0264-410X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9138.628000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 5815.xml